News Article | November 10, 2016
Global Neurovascular Devices Market is poised to grow at a CAGR of 8.1% over the forecast period 2015 to 2022. Increasing ageing population, rising market demand for effective neurovascular devices are some of the key factors driving the market growth. In progress healthcare reforms in the U.S. is restraining the growth of neurovascular devices market. One of the key challenges in neurovascular devices market is the stringent regulatory policies. In 2015, aneurysm coiling and embolization devices segment is estimated for the largest share. Asia Pacific is expected to grow at the highest CAGR, due to increasing awareness among neurologists related to benefits of interventional neurology devices and falling prices of neurovascular devices in Asia Pacific. Some of the key players in the market include Abbott Laboratories, Johnson & Johnson, Medikit Co., Ltd, Medtronic, plc, Merit Medical Systems, Inc., Microport Scientific Corporation, Penumbra, Inc., Terumo Corporation, Stryker Corporation, W. L. Gore & Associates, Inc., Cardiatis, S.A., ITGI Medical Ltd., Bayer AG, Covidien (ev3), Boston Scientific Corporation and Chestnut Medical Technologies. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements 1 Executive Summary 2 Preface 2.1 Abstract 2.2 Stake Holders 2.3 Research Scope 2.4 Research Methodology 2.4.1 Data Mining 2.4.2 Data Analysis 2.4.3 Data Validation 2.4.4 Research Approach 2.5 Research Sources 2.5.1 Primary Research Sources 2.5.2 Secondary Research Sources 2.5.3 Assumptions 3 Market Trend Analysis 3.1 Introduction 3.2 Drivers 3.3 Restraints 3.4 Opportunities 3.5 Threats 3.6 End User Analysis 3.7 Product Analysis 3.8 Technology Analysis 3.9 Emerging Markets 4 Porters Five Force Analysis 4.1 Bargaining power of suppliers 4.2 Bargaining power of buyers 4.3 Threat of substitutes 4.4 Threat of new entrants 4.5 Competitive rivalry Continued.... About Us Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Tidswell M.,Chestnut Medical |
LaRosa S.P.,Brown University
Expert Review of Anti-Infective Therapy | Year: 2011
The human innate immune system initiates inflammation in response to bacterial molecules, particularly Gram-negative bacterial endotoxin. The steps by which endotoxin exposure leads to systemic inflammation include binding to Toll-like receptor-4 that specifically recognizes endotoxin and subsequently triggers cellular and molecular inflammatory responses. Severe sepsis is a systemic inflammatory response to infection that induces organ dysfunction and threatens a person's survival. Severe sepsis is frequently associated with increased blood levels of endotoxin. It is a significant medical problem that effects approximately 700,000 patients every year in the USA, resulting in 250,000 deaths. Eritoran tetrasodium is a nonpathogenic analog of bacterial endotoxin that antagonizes inflammatory signaling by the immune receptor Toll-like receptor-4. Eritoran is being evaluated for the treatment of patients with severe sepsis. © 2011 Expert Reviews Ltd.
Rothberg M.B.,Cleveland Clinic |
Pekow P.S.,Chestnut Medical |
Priya A.,Chestnut Medical |
Lindenauer P.K.,Chestnut Medical
Annals of Internal Medicine | Year: 2014
Background: Most U.S. hospitals publicly report 30-day riskstandardized mortality rates for pneumonia. Rates exclude severe cases, which may be assigned a secondary diagnosis of pneumonia and a principal diagnosis of sepsis or respiratory failure. By assigning sepsis and respiratory failure codes more liberally, hospitals might improve their reported performance. Objective: To examine the effect of the definition of pneumonia on hospital mortality rates. Design: Cross-sectional study. Setting: 329 U.S. hospitals. Patients: Adults hospitalized for pneumonia (as a principal diagnosis or secondary diagnosis paired with a principal diagnosis of sepsis or respiratory failure) between 2007 and 2010. Measurements: Proportion of patients with pneumonia coded with a principal diagnosis of sepsis or respiratory failure and riskstandardized mortality rates excluding versus including a principal diagnosis of sepsis or respiratory failure. Results: When the definition of pneumonia was limited to patients with a principal diagnosis of pneumonia, the risk-standardized mortality rate was significantly better than the mean in 4.3% of hospitals and significantly worse in 6.4%. When the definition was broadened to include patients with a principal diagnosis of sepsis or respiratory failure, this rate was better than the mean in 11.9% of hospitals and worse in 22.8% and the outlier status of 28.3% of hospitals changed. Among hospitals in the highest quintile of proportion of patients coded with a principal diagnosis of sepsis or respiratory failure, outlier status under the broader definition improved in 7.6% and worsened in 40.9%. Among those in the lowest quintile, 20.0% improved and none worsened. Limitation: Only inpatient mortality was studied. Conclusion: Variation in use of the principal diagnosis of sepsis or respiratory failure may bias efforts to compare hospital performance regarding pneumonia outcomes. Primary Funding Source: Agency for Healthcare Research and Quality. © 2014 American College of Physicians.
Rousou J.A.,Chestnut Medical
Journal of Cardiac Surgery | Year: 2013
Background: Fibrin sealants are used for hemostasis and tissue adherence. Aim of Study This systematic review summarizes published clinical data for fibrin sealant use in cardiovascular surgery. Methods: A literature search for the following terms was conducted using PubMed and EMBASE: (TISSEEL or Tissucol or Beriplast P or Evicel or Quixil or Crosseal or Reliseal or Fibringluraas or Bolheal or Tachosil or Vivostat or Vitagel or Artiss or "fibrin glue" or "fibrin sealant" or "fibrin tissue adhesive") and (cardiac or cardiovascular or vascular or heart or coronary or surgery). Case reports and series were excluded; although reports of controlled trials were preferred, uncontrolled trial data were also considered. Results: Clinical trials and chart review analyses of fibrin sealants were identified and summarized. Although clinical trial data were available for other agents, the majority of published studies examined TISSEEL. Overall, TISSEEL and other fibrin sealants showed improvements over standard of care or control groups for a variety of predefined endpoints. Safety findings are also summarized. Conclusions: Data from these studies showed that fibrin sealants were well tolerated and provided effective hemostasis in a range of cardiac and aortic surgeries. © 2013 Wiley Periodicals, Inc.
Graves B.W.,Chestnut Medical
Journal of Midwifery and Women's Health | Year: 2010
As the obesity epidemic increases, primary care clinicians are encountering obesity and health problems associated with obesity more frequently than ever before. In 2007, 41% of women were classified as obese, with a body mass index (BMI) of 30 or higher. Non-Hispanic blacks and Hispanics are more likely to be obese than white, non-Hispanics. A wide spectrum of health problems has been associated with obesity, including cardiovascular disease, diabetes, metabolic syndrome, osteoarthritis, and polycystic ovary syndrome. Obesity has been shown to be a low-grade inflammatory state, which may be responsible for many of the comorbidities. The general consensus recommends screening for obesity and counseling to promote weight loss. In some cases, pharmacotherapy and or bariatric surgery may be recommended. © 2010 American College of Nurse-Midwives.
Mithoefer K.,Chestnut Medical
The journal of knee surgery | Year: 2013
The purpose of this article is to provide an overview and perspective of the available options for clinical outcomes evaluation of articular cartilage repair in the knee. A nonsystematic literature review of reported clinical measures for functional, qualitative, and quantitative structural outcomes evaluation after knee articular cartilage repair was performed. Several outcome scores have been validated for articular cartilage repair in the knee with the International Knee Documentation Committee score, Lysholm score, and Knee injury Osteoarthritis Outcome Score being reported most frequently. Activity measures including Tegner and Marx activity scales and the rate of return to sports have direct practical relevance for athletically active patients. Macroscopic and histological assessment provides important structural information about repair cartilage quality and quantity. In addition, magnetic resonance imaging (MRI) outcome scoring and functional MRI are gaining increasing popularity and promise less invasive systematic assessment. In summary, clinical outcome evaluation after cartilage repair can be performed by various established and validated functional outcome instruments as well as several evolving outcome parameters that provide clinically relevant outcome information for researchers, clinicians, and patients. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Chestnut Medical | Date: 2010-03-24
A multi-layered catheter is provided, having a proximal end, a distal end, and a lumen extending therethrough. The catheter can have various sections of different flexibility extending distally along the length of the catheter. The catheter can have four layers along a proximal portion, and three layers along a distal portion. In some embodiments, the layers can comprise at least a stainless steel coil and a stainless steel braid. The catheter can exhibit both flexibility as well as kink resistance.
Chestnut Medical | Date: 2010-09-08
An intracorporeal grasping device includes a tubular member for entering a lumen of a human body and the tubular member having a distal end portion. An elongated core member is disposed within the interior cavity of the tubular member for rotational or slidable movement within the tubular member and the elongated core member having a proximal end portion and a distal end portion. The elongated core member includes a grasping configuration for capturing an object (e.g., clot or debris) therein.
Chestnut Medical | Date: 2010-03-31
A method of reducing blood flow within an aneurysm includes: injecting a contrast agent into a blood vessel including an aneurysm; deploying an occlusion device across the aneurysm; producing an image of the aneurysm including the contrast agent; and withdrawing the delivery device from the vessel after observing that the aneurysm has been obstructed by a desired amount. The image may be two-dimensional or three-dimensional. Observing that the aneurysm has been obstructed may include determining a degree of obstruction, for example by comparing an area or volume of the contrast agent in a first image and a second image. The desired amount may be a certain degree of obstruction, identification of a shape indicative of stasis such as a flat surface, an approximate hemisphere, a mushroom, or a crescent. If the occlusion device does not achieve the desired amount, a second occluding device may be deployed.
Chestnut Medical | Date: 2011-03-10
A vascular occluding device for modifying blood flow in a vessel, while maintaining blood flow to the surrounding tissue. The occluding device includes a flexible, easily compressible and bendable occluding device that is particularly suited for treating aneurysms in the brain. The neurovascular occluding device can be deployed using a micro-catheter. The occluding device can be formed by braiding wires in a helical fashion and can have varying lattice densities along the length of the occluding device. The occluding device could also have different lattice densities for surfaces on the same radial plane.